Hide metadata

dc.date.accessioned2015-10-06T14:09:58Z
dc.date.available2015-10-06T14:09:58Z
dc.date.created2015-09-28T14:44:19Z
dc.date.issued2015
dc.identifier.citationCAMERON, MARTE Kersten, Christian Vistad, Ingvild van Helvoirt, Rene Weyde, Kjetil Undseth, Christine Mjaaland, Ingvil Skovlund, Eva Fosså, Sophie Dorothea Guren, Marianne . Palliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter study. Radiotherapy and Oncology. 2015, 115(3), 314-320
dc.identifier.urihttp://hdl.handle.net/10852/46171
dc.description.abstractBackground and purpose Radiotherapy is used to palliate pelvic symptoms of castration resistant prostate cancer (CRPC). However, magnitude and time course of effects and toxicities are poorly documented. Study aims were to evaluate changes in patient-reported target symptoms (TS), health-related quality of life (HRQOL) and toxicity following palliative pelvic radiotherapy (PPRT) of CRPC. Material and methods 47 patients with CRPC and a symptomatic pelvic mass prescribed PPRT with 30–39 Gy were prospectively included. Primary endpoint was patient-reported improvement or complete resolution of the TS twelve weeks after PPRT. HRQOL changes were explored. Toxicity was physician-evaluated. Results Lower urinary tract symptoms (LUTS) (45%), hematuria (26%) and pain (19%) were the most common TS. In the 40 evaluable patients, overall TS response twelve weeks after PPRT was 70%. TS responses were 8/18 for LUTS, 11/12 for hematuria, and 7/9 for pain. Global HRQOL improved transiently. The most common toxicity was grade 1 or 2 diarrhea (50%). There was no grade 4 toxicity. Conclusions In the majority of patients with CRPC and a symptomatic pelvic tumor, PPRT with 30–39 Gy contributes to relief of hematuria, pain and other pelvic symptoms, with acceptable toxicity. Future studies should investigate whether PPRT regimens can be simplified.en_US
dc.languageEN
dc.language.isoenen_US
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.titlePalliative pelvic radiotherapy for symptomatic incurable prostate cancer – A prospective multicenter studyen_US
dc.typeJournal articleen_US
dc.creator.authorCameron, Marte
dc.creator.authorKersten, Christian
dc.creator.authorVistad, Ingvild
dc.creator.authorvan Helvoirt, Rene
dc.creator.authorWeyde, Kjetil
dc.creator.authorUndseth, Christine
dc.creator.authorMjaaland, Ingvil
dc.creator.authorSkovlund, Eva
dc.creator.authorFosså, Sophie Dorothea
dc.creator.authorGuren, Marianne
cristin.unitcode185,15,23,30
cristin.unitnameFarmasøytisk biovitenskap
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.cristin1276148
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Radiotherapy and Oncology&rft.volume=115&rft.spage=314&rft.date=2015
dc.identifier.jtitleRadiotherapy and Oncology
dc.identifier.volume115
dc.identifier.issue3
dc.identifier.startpage314
dc.identifier.endpage320
dc.identifier.doihttp://dx.doi.org/10.1016/j.radonc.2015.05.021
dc.identifier.urnURN:NBN:no-50364
dc.type.documentTidsskriftartikkelen_US
dc.type.peerreviewedPeer reviewed
dc.source.issn0167-8140
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/46171/2/Cameron_2015_Pal.pdf
dc.type.versionPublishedVersion


Files in this item

Appears in the following Collection

Hide metadata

Attribution-NonCommercial-NoDerivatives 4.0 International
This item's license is: Attribution-NonCommercial-NoDerivatives 4.0 International